NICE In CDF Rethink Says OK To Bosulif For General NHS Use In CML
Executive Summary
Pfizer Inc.'s Bosulif (bosutinib) will now become generally available on the UK's publicly-funded NHS for use in certain types of chronic myeloid leukemia after NICE reassessed the tyrosine kinase inhibitor in light of new data and a bigger pro-offered price discount from its manufacturer. The drug was previously only available through the country's controversial Cancer Drugs Fund (CDF).